Risk Management Plans for ATMPs
by Maria Schacker
ATMPs are a relatively novel class of medicinal products with anew and very unique set...
Neutralizing Antibody Assay Development – a key consideration for immunogenicity packages
by Jennifer Sales
Neutralising Antibodies, or NAbs, are a subclass of Anti-Drug Antibodies that may be formed during...
Better late than never? What developers of SARS-CoV-2 vaccines in early-to -late-stage development should consider
by Michael Pfleiderer, Ilona Baraniak and Ciaran Greene
Unfortunately, as of today the ongoing pandemic is still far...
Wake up the Sleeping Beauty – Transposons in gene therapy: How do they compare to other genome modifying tools?
by Ewa Janosz
Gene therapy is currently a quickly developing field. Except from commonly known viral vectors and...
Requests for proposals – Get the best value when asking for services
by Timo Liebig
You need a service provider, but which one suits your needs best? Read here how...
AAV gene therapy development: Immunogenicity and safety aspects
by Eveline Molocea and Jörg Schneider
Adeno-associated virus (AAV) is a dominant gene delivery platform that matured in...